Aranthan Jones, II Biography and Net Worth

Insider of Vanda Pharmaceuticals

Aranthan Jones II serves as Chief Corporate Affairs and Communications Officer of the Company. Prior to joining Vanda, Mr. Jones served as Global Head of Public Affairs for Burson Cohn & Wolfe where he counseled Fortune 500 clients on corporate affairs and communications, investor relations and social impact initiatives. Before this position, Mr. Jones II was Chief Policy and Communications Officer at the W.K. Kellogg Foundation, one the world’s largest private philanthropic foundations, where he led the organization’s communications function, public-private-partnerships, and public policy initiatives. Previous to joining the Foundation, Mr. Jones served as Worldwide Head of Government Affairs for Gilead Sciences and led the company’s global public policy and regulatory systems engagement efforts to expand access and accelerate pharmaceutical innovation. Earlier in his career, Mr. Jones was the policy director for the U.S. House of Representatives’ Office of the Majority Whip and was directly responsible for crafting healthcare and financial services legislation. Throughout his career, he has also worked globally in Asia, Africa, Middle East and Europe. Mr. Jones received his Bachelor of Arts degree in sociology and anthropology from Iowa State University.

What is Aranthan Jones, II's net worth?: The estimated net worth of Aranthan Jones, II is at least $586,539.40 as of March 15th, 2021. Mr. Jones, II owns 111,935 shares of Vanda Pharmaceuticals stock worth more than $586,539 as of April 18th. This net worth evaluation does not reflect any other investments that Mr. Jones, II may own. Learn More about Aranthan Jones, II's net worth.
How do I contact Aranthan Jones, II?: The corporate mailing address for Mr. Jones, II and other Vanda Pharmaceuticals executives is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at [email protected]. Learn More on Aranthan Jones, II's contact information.
Has Aranthan Jones, II been buying or selling shares of Vanda Pharmaceuticals?: Aranthan Jones, II has not been actively trading shares of Vanda Pharmaceuticals in the last ninety days. Most recently, Aranthan Jones II sold 16,824 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $16.49, for a transaction totalling $277,427.76. Learn More on Aranthan Jones, II's trading history.
Who are Vanda Pharmaceuticals' active insiders?: Vanda Pharmaceuticals' insider roster includes Phaedra Chrousos (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), and Joakim Wijkstrom (CMO). Learn More on Vanda Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vanda Pharmaceuticals?: In the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 43,036 shares worth more than $271,424.76. The most recent insider tranaction occured on August, 21st when CMO Joakim Wijkstrom sold 3,724 shares worth more than $21,748.16. Insiders at Vanda Pharmaceuticals own 7.7% of the company. Learn More about insider trades at Vanda Pharmaceuticals.
Information on this page was last updated on 8/21/2023.

Aranthan Jones, II Insider Trading History at Vanda Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/15/2021	Sell	16,824	$16.49	$277,427.76
7/26/2021	Sell	7,250	$19.69	$142,752.50
3/15/2021	Sell	18,000	$17.72	$318,960.00	111,935
7/27/2020	Sell	7,313	$10.62	$77,664.06	82,687

Aranthan Jones, II Buying and Selling Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $5.07

$5.05

$5.25

50 Day Range

MA: $4.20

$3.75

$5.24

2 Week Range

Now: $5.07

$3.30

$7.00

Volume

705,024 shs

Average Volume

2,044,894 shs

Market Capitalization

$291.73 million

P/E Ratio

101.42

Dividend Yield

N/A

Beta

0.76

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report